[18F]NaF PET/CT as a Marker for Fibrodysplasia Ossificans Progressiva: From Molecular Mechanisms to Clinical Applications in Bone Disorders

Jolien Zwama; Neeltje M Rosenberg; Vincent A Verheij; Pieter G H M Raijmakers; Maqsood Yaqub; Esmée Botman; Ruben D de Ruiter; Mark R Garrelfs; Arend Bökenkamp; Dimitra Micha; Lothar A Schwarte; Bernd P Teunissen; Adriaan A Lammertsma; Ronald Boellaard; Elisabeth M W Eekhoff

doi:10.3390/biom14101276

[¹⁸F]NaF PET/CT as a Marker for Fibrodysplasia Ossificans Progressiva: From Molecular Mechanisms to Clinical Applications in Bone Disorders

Biomolecules. 2024 Oct 10;14(10):1276. doi: 10.3390/biom14101276.

Authors

Jolien Zwama^{1

2

3

4}, Neeltje M Rosenberg^{1

2

3

4}, Vincent A Verheij^{1

3

4}, Pieter G H M Raijmakers^{4

5}, Maqsood Yaqub^{4

5}, Esmée Botman^{1

4}, Ruben D de Ruiter^{1

4

6}, Mark R Garrelfs^{4

7}, Arend Bökenkamp^{4

8}, Dimitra Micha^{2

3

4

9}, Lothar A Schwarte^{4

10}, Bernd P Teunissen^{4

5}, Adriaan A Lammertsma^{4

5

11}, Ronald Boellaard^{4

5}, Elisabeth M W Eekhoff^{1

2

3

4}

Affiliations

¹ Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Endocrinology and Metabolism, De Boelelaan 1117, Amsterdam, The Netherlands.
² Amsterdam Movement Sciences, Tissue Function and Regeneration, Amsterdam, The Netherlands.
³ Amsterdam Reproduction and Development, Amsterdam, The Netherlands.
⁴ Rare Bone Disease Centre, Amsterdam, The Netherlands.
⁵ Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, De Boelelaan 1117, Amsterdam, The Netherlands.
⁶ Dijklander Hospital, Maelsonstraat 3, 1624 NP Hoorn, The Netherlands.
⁷ Amsterdam UMC location University of Amsterdam, Department of Pediatric Endocrinology, Emma Children's Hospital, Meibergdreef 9, Amsterdam, The Netherlands.
⁸ Amsterdam UMC location University of Amsterdam, Department of Pediatric Nephrology, Emma Children's Hospital, Meibergdreef 9, Amsterdam, The Netherlands.
⁹ Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Human Genetics, De Boelelaan 1117, Amsterdam, The Netherlands.
¹⁰ Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Anesthesiology, De Boelelaan 1117, Amsterdam, The Netherlands.
¹¹ Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a rare genetic bone disorder characterized by episodic flare-ups in connective tissue, which are frequently followed by the formation of heterotopic ossification. The absence of available plasma-soluble biomarkers for flare-ups or heterotopic bone formation poses severe challenges to the monitoring of disease activity to measure or predict disease progression. Recently, 18-fluor-sodium fluoride positron emission tomography/computed tomography ([¹⁸F]NaF PET/CT) was introduced as a potential marker for ossifying FOP activity. This review discusses the pharmacokinetics of [¹⁸F]NaF in relation to the pathophysiology of FOP, and its use as a marker of local bone metabolism in a variety of bone-related disorders. In addition, the review specifically addresses the applicability of [¹⁸F]NaF PET/CT imaging in FOP as a monitoring modality.

Keywords: 18F-sodium fluoride (18F-NaF); fibrodysplasia ossificans progressiva; heterotopic ossification; musculoskeletal development; osteoblasts; positron emission tomography/computed tomography (PET/CT); rare bone diseases.

Publication types

Review

MeSH terms

Animals
Biomarkers* / metabolism
Fluorine Radioisotopes*
Humans
Myositis Ossificans* / diagnostic imaging
Myositis Ossificans* / genetics
Myositis Ossificans* / metabolism
Positron Emission Tomography Computed Tomography* / methods
Sodium Fluoride*

Substances

Sodium Fluoride
Biomarkers
Fluorine Radioisotopes
Fluorine-18

Grants and funding

This research received no external funding.